Versant Ventures Seizes 5.6 M Shares of Lycia Therapeutics Immediately Post‑IPO, Bolstering Confidence in LYTAC Pipeline.

Versant Ventures VII GP, L.P. Buys Big Stakes as Lycia Goes Public

The most recent insider filing shows Versant Ventures VII GP, L.P. (VV VII GP) purchasing 5,631,425 shares of Lycia Therapeutics’ common stock on 26 October 2026, just hours after the company closed its upsized initial public offering. The transaction was executed at the closing price of $25.05 per share, a marginal 0.16 % dip from the IPO price, and represents a sizable allocation of capital from a seasoned biotech investor. At the same time, VV VII GP sold all of its Series A and Series B preferred holdings that were automatically converted into common shares at the IPO, ensuring that the entire purchase is reflected in the new public equity base.

Implications for Investors and the Company’s Trajectory

The timing of this purchase signals confidence in Lycia’s LYTAC platform and its pipeline of protein‑degrading therapeutics. VV VII GP’s investment comes at a critical juncture: the company has just completed an upsized offering that raised $365 million, positioning it to accelerate clinical development and potentially broaden its product portfolio. A high‑profile institutional buy can stabilize early trading, improve liquidity, and send a positive signal to the market. For investors, the move suggests that the firm’s valuation is now perceived as attractive enough to warrant a significant stake, even as the stock sits just below the 52‑week high of $36.49.

Versant Ventures’ Historical Pattern

VV VII GP has a history of deploying capital into biotech companies that are either in pre‑clinical or early clinical stages. Historically, the firm has bought common stock while divesting preferred interests once a company goes public, mirroring the pattern seen here. This strategy reduces dilution risk for the GP and aligns the LP’s interests with the public market performance. Previous transactions by the same entity often involved large block purchases (in the millions of shares) at or near IPO prices, reflecting a willingness to commit substantial capital to high‑potential assets.

What This Means for Lycia’s Future

With a robust capital base and a credible institutional backer, Lycia is well positioned to fund its next clinical milestones, including the phase 1 evaluation of LCA‑0061 for allergic disease and the expansion of its IgE‑targeted pipeline. The presence of VV VII GP on the board of directors (as implied by the filing) could also facilitate access to additional capital and strategic partnerships. Market participants should watch for subsequent insider activity—particularly any further purchases by VV VII GP or its LPs—as this will reinforce sentiment around the company’s growth prospects.

Takeaway

Versant Ventures VII GP’s sizable purchase of common stock immediately after Lycia’s IPO underscores a bullish stance on the LYTAC platform and the company’s clinical roadmap. The transaction aligns with the GP’s historical investment pattern of backing biotech firms through IPOs, converting preferred to common shares, and supporting growth with fresh equity. For investors, the move suggests a potentially strong upside if Lycia successfully progresses its pipeline and monetizes its proprietary technology.